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Abstract 
Acute heart failure and in particular, cardiogenic shock are associated with high morbidity 
and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as 
catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. 
Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve 
systolic function putatively without elevating intracellular Ca2+. Although meta-analyses of 
smaller trials suggested that levosimendan is associated with a better outcome than 
dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv 
mecarbil, phase II clinical trials suggest a favorable hemodynamic profile in patients with 
acute and chronic heart failure, and a phase III morbidity/mortality trial in patients with 
chronic heart failure has recently begun. Here, we review the pathophysiological basis of 
systolic dysfunction in patients with heart failure and the mechanisms through which different 
inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen 
species production in mitochondria are intimately linked to the processes of excitation-
contraction coupling, we also discuss the impact of inotropic agents on mitochondrial 
bioenergetics and redox regulation. Therefore, this position paper should help identify novel 
targets for treatments that could not only safely improve systolic and diastolic function 
acutely, but potentially also myocardial structure and function over a longer term.   
 
Key words 
Heart failure, acute decompensated heart failure, inotropes, cardiogenic shock, excitation-
contraction coupling, calcium, sarcomeres, mitochondria, energetics, adrenergic receptors, 
contractility, levosimendan, omecamtiv mecarbil, nitroxyl.  
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Introduction 
Heart failure (HF) is a leading cause for hospital admissions in developed countries 
worldwide,1 and its incidence is further increasing as average life expectancy rises. While 
the prognosis of patients with chronic HF has improved over the last decades, the 
prognosis of acute HF is still poor. Although only a small percentage of patients with acute 
HF present with cardiogenic shock (~3%) and/or signs of hypoperfusion (~15%), their in-
hospital mortality is much higher than of patients with acute HF without these severe 
conditions.2 An important treatment option in these patients is inotropic agents to acutely 
increase cardiac output.3 However, since the use of most inotropic agents (in particular, 
catecholamines and PDE-inhibitors) is complicated by adverse short- and long-term effects, 
their use is not recommended in the absence of hypotension or hypoperfusion.3 On the 
other hand, the oldest inotropic agent (digitalis) can be safely applied to patients with 
chronic HF and improves morbidity.4 […] Here, we discuss the detailed mechanisms of 
inotropic agents to estimate which mechanisms of action may provide benefit in either acute 
or chronic HF.  
 
In patients with HF with reduced ejection fraction (HFrEF), the inability of the heart to eject 
sufficient blood for the needs of peripheral tissues is caused by defects of excitation-
contraction (EC) coupling in cardiac myocytes (Figure 1).5 Traditionally, an acute increase 
in cardiac output is achieved with drugs that increase intracellular cyclic adenosine 
monophosphate (cAMP), such as catecholamines or phosphodiesterase (PDE) inhibitors 
(Figure 2). However, these agents increase myocardial oxygen (O2) consumption, 
predispose to life-threatening arrhythmias6 and activate signaling pathways of hypertrophy 
and cell death,7, 8 which may explain why they are associated with adverse outcome.9 
Consequently, recent developments aimed at increasing contractility without increasing 
cAMP or Ca2+ through Ca2+-sensitizing of myofilaments or myosin activation. Although 
meta-analyses with the Ca2+ sensitizer levosimendan suggest an overall benefit,10, 11 larger 
comparative trials failed to show a survival benefit despite hemodynamic improvements.12-15 
The myosin activator omecamtiv mecarbil has passed phase II trials,16-20 and a phase III 
trial was recently launched in patients with chronic HF (GALACTIC-HF; NCT0292932).   
 
Considering the poor outcome of patients in cardiogenic shock and/or signs of 
hypoperfusion2 and the mostly disappointing results of inotropic agents in patients with 
acute HF, novel strategies are urgently needed. To this end, the Committees on 
Translational Research and on Acute Heart Failure of the Heart Failure Association (HFA) 
of the European Society of Cardiology (ESC) developed this position paper that addresses 
the following three key issues:  
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1) Why have classical inotropic agents failed?  
2) Is direct targeting of sarcomere function therapeutically advantageous? 
3) Which novel concepts are promising? 
 
To understand the mechanisms of traditional, current and future medicines, it is essential to 
understand the physiology of EC coupling and its pathological alterations in HF. We will 
also discuss the bioenergetic consequences of inotropic interventions, since these may 
impact the long-term prognosis of HF patients. Finally, we will give recommendations for 
basic and clinical research directed at developing novel strategies for inotropic interventions 
in acute HF.   
 
 
Physiology of excitation-contraction coupling 
During each action potential, Ca2+ enters cardiac myocytes via L-type Ca2+ channels 
(LTCC), triggering even greater Ca2+ release from the Ca2+ stores of the cell, i.e., the 
sarcoplasmic reticulum (SR; Figure 1). This Ca2+ binds to troponin C, facilitating actin-
myosin interaction that induces the contraction of the heart muscle. During diastole, Ca2+ 
diffuses away from troponin C, initiating relaxation. The Ca2+ that was released from the SR 
is taken back up by the SR Ca2+ ATPase (SERCA), whereas the amount of Ca2+ that 
entered the cell via LTCCs is exported by the Na+/Ca2+ exchanger (NCX).4  
 
Cardiac contractility is increased by three principle mechanisms:  
1) β-Adrenergic stimulation, 
2) the Frank-Starling mechanism and 
3) the positive force-frequency relation (also known as “Bowditch-Treppe”).  
 
Noradrenaline (NA) is released from sympathetic nerve endings in the myocardium and 
stimulates β1-adrenergic receptors (β1-ARs), which couple to the stimulatory G-protein (Gs) 
and activate the adenylyl cyclase (AC) to produce cAMP (Figures 1 and 2). Cyclic AMP 
activates protein kinase A (PKA) which (through phosphorylation) activates LTCCs, 
accelerates SERCA, increases SR Ca2+ release via ryanodine receptors (RyRs) and 
decreases myofilament Ca2+ affinity. Furthermore, cAMP activates the exchange protein 
directly activated by cAMP (Epac), further activating Ca2+/Calmodulin-dependent protein 
kinase II (CaMKII) which phosphorylates various Na+- and Ca2+-transporting proteins, 
mostly synergistic with PKA-mediated actions (Figure 2).21 The net result is an increase 
and acceleration of force generation and relaxation (positive inotropic and lusitropic effects), 
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maintaining the refilling of the ventricles at elevated heart rates (positive chronotropic 
effect). In the human heart, the breakdown of cAMP is governed primarily by PDE3 and to a 
lesser extent by PDE4.22 
 
Besides β-AR stimulation, the “Bowditch Treppe” increases cardiac contractility at elevated 
heart rates. This is explained by slower Ca2+-efflux (via the NCX) than -influx kinetics (via 
LTCCs), which results in intracellular accumulation of Ca2+ at higher heart rates that is 
sequestered into the SR by SERCA, from where it is released in greater amounts on the 
ensuing beat. The Frank Starling mechanism is caused by a length-dependent increase of 
the Ca2+ affinity of the myofilaments, resulting in stronger contraction at unchanged 
cytosolic Ca2+ concentrations ([Ca2+]c).  
 
 
Pathophysiological changes of excitation-contraction coupling in 
heart failure 
The central deficit of EC coupling in myocytes from failing hearts is a decreased Ca2+ load 
of the SR. This is primarily the result of reduced SERCA expression and activity and a Ca2+ 
leak from the SR via RyRs, reducing systolic SR Ca2+ release and thereby the activator 
Ca2+ at the myofilaments (Figure 1).5 The reduced rate of SERCA-mediated Ca2+ re-uptake 
into the SR also slows relaxation. Furthermore, the cytosolic Na+ concentration ([Na+]i) is 
elevated in failing cardiac myocytes through changes in the “late Na+ current” (late INa), 
Na+/H+ exchanger (NHE) and Na+/K+-ATPase (NKA) activities.23 While this facilitates Ca2+-
influx via the reverse-mode of the NCX during the action potential,5 partly compensating for 
decreased systolic SR Ca2+ release,24 relaxation is further slowed by hampering diastolic 
Ca2+ extrusion via the forward-mode NCX. This is particularly problematic at higher heart 
rates, when diastole progressively shortens. Consequently, the normally positive force-
frequency relationship is blunted or even negative in failing human hearts, mediated by a 
variable combination of elevated diastolic [Ca2+]c and tension as well as decreased SR Ca2+ 
load and release.25, 26 This decreases left ventricular ejection fraction (LVEF) and cardiac 
output at higher heart rates in vivo.27 Finally, elevated diastolic [Ca2+]c and increased open 
probability of RyRs increases the probability of spontaneous SR Ca2+ release events, which 
(by subsequent Ca2+ extrusion via the electrogenic NCX) can induce delayed after-
depolarizations, a well-defined trigger of ventricular arrhythmias.  
 
In addition to the defects in ion handling and the ensuing inversion of the force-frequency 
relationship, continuous stimulation of cardiac β1-ARs through activation of the sympathetic 
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nervous system desensitizes and downregulates β1-ARs (Figure 2),7, 8 blunting their 
response to endogenous or exogenous catecholamines. Consequently, phosphorylation of 
several Ca2+ handling proteins is reduced. In failing hearts, the Ca2+ affinity of the 
myofilaments is increased as a result of decreased PKA-mediated phosphorylation of 
troponin I,28, 29 although this issue is not fully settled yet.30  
 
 
Energetic aspects 
EC coupling requires high amounts of energy in the form of ATP, which is replenished by 
oxidative phosphorylation in mitochondria. During β-adrenergic stimulation, mitochondria 
take up Ca2+ to stimulate the Krebs cycle, which produces NADH as the main electron 
donor for ATP production at the respiratory chain (Figure 3).31 Mitochondrial function is 
impaired in HF, resulting in energetic deficit and oxidative stress (Figure 3).31-33 
Mitochondrial dysfunction is linked to defects in EC coupling, since the Krebs cycle requires 
stimulation of its key enzymes by Ca2+, and decreased SR Ca2+ release hampers 
mitochondrial Ca2+ uptake via the uniporter (MCU). In addition, elevated [Na+]i accelerates 
mitochondrial Ca2+ efflux via the mitochondrial Na+/Ca2+ exchanger (NCLX; Figure 3). 
Impaired Krebs cycle activity limits NADH-dependent ATP production at the respiratory 
chain and provokes excess emission of reactive oxygen species (ROS) through depletion of 
the NADPH-dependent anti-oxidative capacity, causing oxidative stress.31 Reduced ATP 
production can limit the contractile reserve of the LV,34 and most Na+ and Ca2+ transporting 
mechanisms are sensitive to redox-dependent modifications.35 Thus, the tight interplay 
between EC coupling and mitochondrial energetics (Figure 3) can set in motion a vicious 
cycle of deteriorated ion handling, energetic deficit and oxidative stress to aggravate 
systolic and diastolic dysfunction in HF.  
 
In patients with HF, iron deficiency (ID) predicts adverse outcome,36 while iron 
supplementation improves functional capacity and quality of life.37 In failing hearts, 
myocardial iron content is reduced and associated with reduced activity of Krebs cycle 
dehydorgenases and expression of antioxidative enzymes.38 In preclinical models, severe 
cardiac or skeletal muscle ID perturbs mitochondrial function and induces systemic 
metabolic derangements and cardiomyopathy.39, 40 Accordingly, ID may further aggravate 
energy supply and demand mismatch and oxidative stress in HF. However, since plasma ID 
does not directly correlate with myocardial ID, these issues require further investigation (for 
more in-depth discussion see Ref.41).  
“Classical” inotropic agents 
8 
 
 
Digitalis 
Digitalis-derived cardiotropic glycosides (CTG) are the oldest inotropic drugs and increase 
[Na+]i in cardiomyocytes by inhibiting Na+ export via the NKA (Figure 4). [Na+]i 
accumulation hampers diastolic Ca2+ extrusion via the NCX and supports Ca2+ influx via the 
reverse mode NCX during systole, thereby increasing diastolic [Ca2+], Ca2+ transient 
amplitudes and consequently, inotropy (Figure 4). On the other hand, elevated [Na+]i 
accelerates mitochondrial Ca2+ efflux via the NCLX, reducing Ca2+-activation of the Krebs 
cycle and its regeneration of NADH and NADPH. Since NADPH is required for anti-
oxidative enzymes to detoxify ROS (Figure 3), CTG-induced NADPH oxidation increases 
mitochondrial ROS emission and thereby arrhythmias (Figure 4).42 The pro-arrhythmic 
actions of CTG narrow its therapeutic range.43  
 
In patients with HFrEF, digoxin may be considered in symptomatic patients in sinus rhythm 
despite treatment with an ACE-inhibitor (or angiotensin receptor blocker), a β-blocker and a 
mineralocorticoid antagonist to reduce the risk of hospitalizations (class IIb, B3). However, 
the Digitalis Investigation Group (DIG) Trial4 was conducted before β-blockers became a 
mainstay of HF therapy, and digoxin did not improve all-cause mortality, but reduced 
hospitalization due to HF worsening. At the lower dosages used in current practice, digitalis 
may be preferentially a modulator of autonomic tone and less inotropic stimulator.44 The 
ongoing DIGIT-HF study prospectively investigates the role of digitoxin in patients with 
HFrEF already on current guideline-adherent therapy (http://digit-hf.de). In atrial fibrillation, 
clinical evidence is limited to small and observational studies, and there is an ongoing 
debate on potentially increased mortality.45 However, prescription bias in the retrospective 
analyses likely mimics the perceived digoxin driven mortality.46 In the current HF 
Guidelines, an intravenous bolus of digoxin should be considered in digoxin-naïve-patients 
with New York Heart Association (NYHA) class IV patients and rapid ventricular rate to slow 
heart rate (Class IIa, B).3 
 
 
Catecholamines 
The three endogenous catecholamines dopamine, adrenaline and noradrenaline stimulate 
β1-ARs, and to variable degrees also α1- and β2-ARs and dopaminergic D1- and D2-
receptors (Table 1).6 Thus, their hemodynamic actions are not limited to increasing cardiac 
contractility via β1-ARs (Figure 2). In fact, α1-AR-mediated vasoconstriction by adrenaline 
and noradrenaline (Table 1) renders them useful in patients with septic shock where 
vasodilation underlies hypotension. The hemodynamic profile of dopamine, the immediate 
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precursor to noradrenaline in the synthetic pathway, is dominated by vasodilation at low 
concentrations at which binding to dopaminergic D1- and D2-receptors increases blood flow 
to the heart, brain, kidney and various other organs. Its traditional use to increase renal 
blood flow, however, was discouraged after neutral effects in trials on patients with acute 
decompensated heart failure, with or without renal dysfunction.47-49 At higher doses, 
dopamine increases blood pressure by vasoconstriction via α1-ARs and positive inotropic 
and chronotropic effects via β-ARs, respectively.   
 
Since in patients with cardiogenic shock, neuroendocrine activation induces vasoconstriction 
and tachycardia, the ideal drug should be positive inotropic without further increasing 
systemic vascular resistance (SVR). Dobutamine fulfils these requirements.50 It is a full 
agonist at β1-ARs, inducing a positive inotropic effect with similar efficacy as isoproterenol, a 
synthetic β1- and β2-AR agonist without any α-AR agonism (Table 1). The affinity of 
dobutamine for β2-AR is ~10-fold lower than for β1-ARs and in particular, its agonist efficacy 
at β2-ARs and α1-ARs much weaker than at β1-ARs.51 Through its dominating inotropic effect 
and mutually offsetting vascular effects of α1- and β2-AR agonism, the decrease of SVR at 
intermediate and higher doses is mediated by reflex withdrawal of the endogenous 
sympathetic tone.52 For any given increase in cardiac contractility, the increase of heart rate 
and blood pressure is lower with dobutamine than with dopamine or noradrenaline, further 
reflecting dobutamine´s selectivity for β1- over β2- and α1-ARs.50 However, this favorable 
hemodynamic profile comes at the cost of elevated myocardial oxygen (O2) consumption50, 52 
and arrhythmias. Noradrenaline may be considered in patients who have cardiogenic shock, 
despite treatment with another inotrope to increase blood pressure and vital organ 
perfusion.3 The combination of adrenaline with dobutamine, however, appears to portend a 
particular risk for adverse outcome.53  
 
In patients with HF, elevated plasma noradrenaline levels predict adverse outcome.54 
Chronic β-AR stimulation desensitizes and downregulates β-ARs via PKA, GRK2 (also 
known as β-ARK1) and β-arrestin.7, 8, 55 Furthermore, β-arrestin activates CaMKII which 
sustains contractility despite desensitization of β-ARs from PKA-mediated inotropy (Figure 
2).21 CaMKII activation, however, is a major driver of cardiac arrhythmias.56 The net 
functional consequence of all these processes is a decreased responsiveness of the human 
failing heart to β-AR stimulation. Therefore, despite its favourable short-term hemodynamic 
profile that improves symptoms,9 dobutamine treatment is associated with tolerance,57 
arrhythmias and mortality, respectively.58, 59 
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PDE Inhibitors 
To overcome desensitization and downregulation of cardiac β-ARs as well as their 
blockade through β-blockers, PDE-inhibitors were developed. In human failing myocardium, 
inhibition of PDE3, but not PDE4 potentiates β-AR mediated positive inotropic effects.60 
Conversely, in human atrial myocardium, inhibition of PDE4 potentiates arrhythmias 
induced by both β1- and β2-AR stimulation, while PDE3 inhibition only potentiates β1-AR-
induced arrhythmias.61 PDE-inhibitors also decrease SVR through cAMP-mediated 
vasodilation, which is beneficial in patients with acute HF and high SVR, but limits its 
application in patients with cardiogenic shock due to reductions in blood pressure. In 
patients with HF treated with β-blockers, the efficacy and potency of PDE-inhibitors is 
maintained, while the effects of dobutamine are blunted.62  
 
Why have classical inotropes failed?  
Currently, dobutamine, dopamine and PDE-inhibitors are recommended in patients with 
hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite adequate 
filling status to increase cardiac output and blood pressure and to improve peripheral 
perfusion and maintain end-organ function (IIb, C).3 However, while in analyses that 
evaluated cAMP-dependent inotropes in general, their short term use yielded neutral 
effects, longer term use was associated with adverse outcome in patients hospitalized for 
acute HF despite improved quality of life.58, 63, 64 Therefore, inotropic agents are explicitly 
restricted to patients that fulfil the above mentioned criteria and are not recommended for 
any other patients (class IIIA).3 The adverse long-term effects may be related to PKA- and 
CaMKII-induced maladaptive cardiac remodeling through inducing hypertrophy, apoptosis 
and fibrosis (Figure 2).7, 8 In particular, activation of β1-ARs induces apoptosis,65 which is an 
important mechanism for LV remodelling and dysfunction in HF.66, 67 Furthermore, β-
adrenergic activation alters myocardial substrate utilization and thereby, may trigger 
energetic deficit and oxidative stress.59 These data indicate that despite their favourable 
acute hemodynamic profile, the use of adrenergic agonists and PDE-inhibitors leads to 
adverse outcome by triggering maladaptive cardiac remodelling and arrhythmias, while vice 
versa, antagonizing β1-ARs can reverse remodelling, improve LV function and prolong 
survival.7 Therefore, a new generation of inotropes had to be developed to avoid activation 
of adrenergic pathways and increase contractility without raising Ca2+, which is pro-
arrhythmic and causes higher energy consumption through activation of Ca2+ transporting 
systems.   
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Treatments targeting sarcomeres 
 
Ca2+ sensitizers 
Ca2+ sensitizers shift the relationship between [Ca2+]c and force development of sarcomeres 
(i.e., the pCa-force relationship) to the left, increasing force at any given [Ca2+]c. They were 
developed in the early 1980s as cardiotonic agents with a number of theoretical advantages 
over catecholamines and PDE-inhibitors:  
 
(i) Ca2+ sensitizers should neither increase trans-sarcolemmal influx of Ca2+ nor 
alter SR Ca2+ fluxes during systole or diastole. This should be less pro-
arrhythmic and less energy consuming.  
(ii) Ca2+ sensitizers should not affect heart rate or blood pressure if a compound 
was selective for cardiac myofilaments, which may have positive effects on 
energetics.  
(iii) Ca2+ sensitizers should be independent of the desensitized β-AR/cAMP system 
in HF and should themselves not induce tolerance. 
 
Examples of this class of drugs are EMD-57033, CGP-48506, pimobendan and 
levosimendan. The mechanisms of Ca2+ sensitization differ between Ca2+ sensitizers. While 
levosimendan and pimobendan increase the affinity of troponin C to bind Ca2+,68-70 CGP-
48506 acts downstream of troponin C, and EMD 57033 affects the actin-myosin interaction 
by direct binding to the myosin motor domain.71, 72 Independent of the mechanism, the shift of 
the pCa2+-force curve to the left increases systolic force generation for any given [Ca2+]c, but 
on the other hand impedes relaxation following the decrease in [Ca2+]c. The slowing of 
diastolic relaxation is an inherent property of pure Ca2+ sensitizers and may be the reason 
why most pharmaceutical companies stopped their development. In this context, mutations in 
sarcomeric proteins that cause hypertrophic cardiomyopathy (HCM) commonly increase 
myofilament Ca2+ sensitivity as a unifying disease mechanism.73, 74 Moreover, both HCM 
mutations and drugs that increase Ca2+ sensitivity are arrhythmogenic, presumably by 
providing a sink for Ca2+ that is released during diastole, causing depolarisations via the 
electrogenic NCX.75, 76  
 
Levosimendan 
In contrast to CGP-48506, levosimendan does not prolong relaxation time or compromise 
diastolic relaxation. Thus, it does not have the same profile as pure Ca2+ sensitizers. The 
most likely reason is that levosimendan is not only a Ca2+ sensitizer binding to troponin C,69 
but also a potent and selective PDE3-inhibitor with an IC50 in the nanomolar range, but 
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~1000-fold lower affinity for PDE4.77, 78 Accordingly, levosimendan increases cAMP with 
similar potency as it increases force.79 Furthermore, its positive inotropic effect is abolished 
by the muscarinic receptor agonist carbachol, which acts through inhibiting cAMP 
generation. Also in human myocardium, the inotropic effects of levosimendan require β-
adrenergic pre-stimulation and/or elevations of [Ca2+]c and can be prevented by PDE3-, but 
not PDE4-inihibition.80-82  
 
Levosimendan´s clinical activity during long-term treatment is mainly governed by its active 
metabolite OR-1896, which has a much longer half-life (81 vs. 1 h83). OR-1896 stimulated 
contractile force with a roughly similar potency as levosimendan, had a 4.5-fold lower 
potency as a Ca2+ sensitizer and a 38-fold lower potency as a PDE3 inhibitor.78 Yet, even 
the inotropic effect of OR-1896 is sensitive to carbachol and therefore likely mediated by 
PDE3 inhibition.84 Therefore, also for OR-1896, a combination of PDE3-inhibition with Ca2+ 
sensitization is the mechanism that is responsible for positive inotropy.  
 
A common alternative explanation why levosimendan does not prolong relaxation (other 
than through PDE3-inhibition) is that levosimendan´s binding to troponin C is Ca2+-
dependent. However, it is currently unclear – if not rather unlikely – whether levosimendan 
can bind and unbind troponin C on a beat-to-beat basis in a millisecond and micromolar 
range, as would be required to explain the lack of relaxation prolongation by this 
mechanism (see the Online Supplement for a detailed discussion of this issue). Besides 
its effects on EC coupling, levosimendan also activates glibenclamide-sensitive 
sarcolemmal ATP-dependent K+-currents (IKATP), which may add to its vasodilating activity 
and potentially provide cardioprotective effects through activation of mitochondrial IKATP (see 
Online Supplement for a more detailed discussion).    
 
These data indicate that for levosimendan, PDE3 inhibition synergizes with Ca2+ 
sensitization for its inotropic action (Figure 5), which may be particularly relevant to human 
failing myocardium in which PDE3 plays the dominant role for controlling intracellular 
cAMP.60 From this it can be predicted that the more β-ARs are pre-activated by 
endogenous or exogenous catecholamines, the more pronounced is the inotropic effect of 
levosimendan, and the more this effect is mediated by PDE3-inibition rather than Ca2+ 
sensitization. Conversely, at low β-AR pre-activation (such as during pharmacological β-
blockade), the Ca2+ sensitization effect of levosimendan may become more important for 
inotropy. In this context, it is interesting to observe that in the SURVIVE trial, patients with 
(but not without) β-blocker pre-treatment had improved short-term survival with 
levosimendan compared to dobutamine.85, 86 Conversely, in patients with septic shock who 
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were all co-treated with catecholamines, levosimendan was associated with higher rates of 
supraventricular tachycardia and a numerical, but non-significant increase in mortality 
(hazard ratio 1.24, p=0.17).87 Therefore, although the clinical evidence for these 
considerations is limited, levosimendan´s PDE3-inhibitory effect may be potentiated through 
pre-activation of β-ARs by endogenous or exogenous catecholamines also under in vivo 
conditions, and such potentiated adrenergic signaling may potentially contribute to 
arrhythmias and adverse consequences for cardiomyocyte biology (Figure 2).    
 
Clinical trials 
Several clinical trials tested the effects of levosimendan in patients with HF, comparing it to 
either placebo or dobutamine. In the LIDO trial, levosimendan improved hemodynamics 
more effectively than dobutamine and was associated with lower mortality than dobutamine 
after 180 days.88 In the SURVIVE trial, however, mortality after 180 days (the primary 
endpoint) was not different between dobutamine and levosimendan despite a more 
favourable hemodynamic profile (BNP reduction) in the first 5 days after randomization.12 
As mentioned above, pre-treatment with a β-blocker was associated with improved short-
term outcome at day 5 in a posthoc analysis.85 
  
In the REVIVE trial,13 levosimendan (compared to placebo) was associated with more 
frequent hypotension and cardiac arrhythmias during the infusion period, and a numerical 
(but insignificant) risk of death despite improved symptoms and reduced plasma BNP 
levels. In a meta-analysis on 5,480 patients in 45 randomized clinical trials, however, 
levosimendan was associated with a 20% relative risk reduction of mortality, and this 
reduction was confirmed in studies with placebo (-18%; p<0.05) or dobutamine as 
comparator (-32%; p<0.005).10 These trends were confirmed by another meta-analysis.11 
However, in these meta-analyses, trials on patients with acute cardiac events were 
combined with trials on patients undergoing elective cardiac surgery. Furthermore, in the 
recent CHEETAH14 and LEVO-CTS15 trials, levosimendan did not improve outcome of 
patients with systolic HF undergoing cardiac surgery, although the use of inotropes 24 
hours after surgery was reduced with levosimendan in LEVO-CTS.15 
 
Several smaller and mostly underpowered trials evaluated the usefulness of repeated 
doses of levosimendan for patients with terminal HF in outpatient settings. Since posthoc- 
and meta-analyses of these smaller trials suggest that levosimendan may have favourable 
effects on hemodynamics, symptoms, rehospitalisation and biomarkers, the initiation of an 
adequately powered trial is warranted.89 
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Taken together, the principle of Ca2+ sensitization alone was no breakthrough in the 
treatment of the common forms of HF, because it is associated with worsening of diastolic 
relaxation, which is already compromised in HF in the first place. The ancillary PDE-
inhibitory effect of levosimendan improves its hemodynamic profile compared to other, 
more pure Ca2+ sensitizers, although this may come at the cost of cAMP-related side 
effects (e.g., arrhythmias). No single trial on its own, however, could so far show superiority 
of levosimendan compared to placebo or a comparator drug.  
 
Based on the clinical profile of levosimendan, the current HF Guidelines make the following 
recommendations for the use of levosimendan:  
• Short-term intravenous infusion of levosimendan may be considered in patients with 
hypotension (SBP <90 mmHg) and/or signs/symptoms of hypoperfusion despite 
adequate filling status to increase cardiac output and improve peripheral perfusion 
and maintain end-organ function (similar to dobutamine, dopamine and PDE-
inhibtors; IIb, C).3 
• When mean arterial pressure needs pharmacological support, a vasopressor 
(preferably noradrenaline) may be used in combination with levosimendan.3  
• An intravenous infusion of levosimendan (or a PDE inhibitor) may be considered to 
reverse the effect of β-blockade if β-blockade is thought to be contributing to 
hypotension with subsequent hypoperfusion (IIb, C).3 
• Levosimendan is not recommended unless the patient is symptomatically 
hypotensive or hypoperfused because of safety concerns (IIIA).3  
 
 
Omecamtiv mecarbil 
Omecamtiv mecarbil (OM) is a small-molecule, selective cardiac myosin activator whose 
therapeutic rationale and discovery were described elsewhere.90, 91 OM binds to the 
catalytic domain of cardiac myosin, stabilizing the pre-powerstroke state,92 thus increasing 
the transition rate of myosin into the strongly actin-bound force-generating state (Figure 
6A)93 and thus increasing cardiac contractility. The pharmacodynamic signature of OM is an 
increase in the systolic ejection time (SET). This is a consequence of the increase in the 
number of myosin heads interacting with actin filaments, facilitating a longer duration of 
systole, even as [Ca2+]c already decays. OM prolongs the time and increases the amplitude, 
but not the rate of cell shortening, and does not interfere with [Ca2+]c transients (Figure 
6B).93  
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A number of dose-finding studies with an intravenous formulation of OM were performed in 
a dog model of HF,94 healthy men17 and patients with acute19 and chronic HF,16 
respectively. In the dog HF model, OM prolonged SET and increased stroke volume (SV; 
Table 2).93, 94 As a consequence, cardiac output increased, thereby decreasing SVR and 
heart rate, presumably through reducing endogenous sympathetic activation.93, 94 Although 
OM might increase ATP turnover at the level of the sarcomere,93 this increase appears to 
be counterbalanced by the reduction in heart rate, SVR (reducing cardiac afterload) and 
end diastolic volume (reducing myocardial wall stress), resulting in no significant change of 
cardiac O2 consumption despite the increase of cardiac output.93, 94 Consequently, cardiac 
efficiency should improve.  
 
In healthy men and patients with stable HF, at comparable increases in SET, however, the 
net increases in SV, cardiac output and the ensuing decreases in heart rate were overall 
smaller than in the preclinical studies, perhaps reflecting the broader range of baseline 
conditions found in human studies (Table 2). In these early studies, OM was studied over a 
broad range of plasma concentrations, in some cases exceeding 1200 ng/ml. Increases in 
SET are noted at plasma concentrations as low as 100-200 ng/ml, while the effect on SV 
appeared to plateau at 400-500 ng/ml. In some individuals, myocardial ischemia developed 
with chest pain, ECG changes and/or troponin rises at plasma concentrations beyond 1200 
ng/ml.16, 17 This may be explained by an excessive increase in SET, prolonging cardiac 
contraction, and progressively shortening diastole (during which coronary perfusion takes 
place).16, 17 In a trial of patients with ischemic cardiomyopathy and angina in daily life, 
however, OM at target plasma concentrations of 295 ng/ml and 550 ng/ml, respectively, did 
not affect symptom-limited exercise capacity in treadmill tests or plasma troponin I levels.18 
Subsequent trials focused on dose regimens that constrain exposure to less than 1000 
ng/ml. 
 
In the ATOMIC-AHF study on patients with AHF and an LVEF ≤40%, the primary endpoint 
of dyspnea relief was not reached by 3 ascending doses of intravenous infusion of OM 
versus placebo.19 However, in the highest dose group (n=202), more patients responded 
with dyspnea relief to OM (51%) than to placebo (37%; p=0.034). In an echocardiographic 
substudy, OM prolonged SET and decreased LV end-systolic dimension, although LV 
stroke volume was not increased.19 Additionally, slight decreases in heart rate (-2 bpm) and 
increases in systolic blood pressure were noted (Table 2).  
 
In the COSMIC-HF trial, oral OM at either a fixed dose (25 mg twice daily) or dosing based 
on a pharmacokinetic titration protocol was tested against placebo in patients with stable 
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(not acute) systolic HF receiving standard of care therapy.20 After 20 weeks, moderate 
increases in SET and SV and a slight reduction in heart rate were noted in the 
pharmacokinetic titration group (Table 2). The latter effect may reflect slightly reduced 
endogenous sympathetic activity.95 Furthermore, the LV end-diastolic volume decreased by 
11 ml and NT-proBNP levels dropped by 970 pg/ml compared to placebo, respectively. As 
in ATOMIC-AHF,19 there was a small increase in cardiac troponin I that did not correlate 
with OM plasma concentrations.16, 17 The frequency of deaths, arrhythmias, hospital 
admissions or adverse events was not different between groups, suggesting safety.  
 
Overall, the hemodynamic profile of OM appears promising within its therapeutic range. The 
increase in cardiac contractility and subsequent prolongation of SET increases LV stroke 
volume in patients with chronic heart failure and consequently, blood pressure should rise 
initially which then may reduce endogenous sympathetic activation. This is indicated by the 
slight though consistent lowering of heart rate in human and animal studies. As a result, 
cardiac output in humans appears largely unchanged despite the modest decrease in heart 
rate, suggesting improved cardiac efficiency. Furthermore, the decrease in LV filling 
pressures, as indicated by the decrease in NT-proBNP in COSMIC-HF or the decrease of 
LV end-diastolic pressures in acute studies in the dog indicate LV unloading that may 
facilitate reverse remodeling of the LV. The now initiated GALACTIC-HF trial 
(NCT02929329), which aims to include 8000 patients with chronic HF will eventually clarify 
the long-term outcome by OM. Meanwhile, some uncertainties remain regarding the 
mechanisms of action of OM and their implications for cardiac function and long-term 
outcome.  
 
Diastolic dysfunction  
In cardiac myocytes, the increase in systolic function by OM comes at the cost of increased 
diastolic tension (Figure 6C), indicated by shortening of diastolic cell length. At low [OM] of 
200-400 nM, systolic improvement outweighs the diastolic deficit in rat cardiac myocytes, 
while at 800 nM, this relation reverses. In an in vivo pig model of myocardial stunning after 
ischemia/reperfusion, OM reduced both end-diastolic and end-systolic volumes to similar 
extents (Figure 6E) at concentrations that prolonged SET by 20% (table 2). Thereby LVEF 
pseudo-increased, while SV did not.96 Furthermore, the OM-induced increase in cardiac 
output was smaller in humans with or without HF compared to the dogs with HF (table 3). 
In light of the results on post-ischemic pigs,96 it needs to be considered whether an 
improvement of SET (and therefore, SV) by OM may have been (partly) offset by decreases 
in end-diastolic volume or filling. The improvement of NT-proBNP by long-term OM in 
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COSMIC-HF,20 however, rather argues against a meaningful deterioration of diastolic 
function by these doses of OM.  
 
Bioenergetic aspects 
In dogs with HF, OM did not increase O2 consumption94 although in the post-ischemic pig 
model, O2 consumption tended to increase.96 In isolated mouse hearts, OM impaired 
myocardial efficacy by increasing O2 consumption in working hearts and during basal 
(resting) metabolism, which was abolished by a myosin-ATPase inhibitor.96 These data 
suggest that OM increases (tonic) myosin ATPase activity97 and thereby O2 consumption, 
which however contrasts with the effect of OM to inhibit the basal ATPase of myosin in 
vitro.98 In skinned rat cardiac myocytes, OM shifted the pCa/force relationship to the left, 
indicative of sensitizing myofilaments to Ca2+ (Figure 6F).99 In human myocardium, OM 
increased the myosin duty ratio which resulted in enhanced Ca2+ sensitivity, but slower force 
development.100 In a mouse model of dilated cardiomyopathy with decreased myofilament 
Ca2+ sensitivity, OM resensitized myofilaments towards control levels.101 However, in the 
majority of patients with HF, the Ca2+ affinity of the myofilaments is increased rather than 
decreased,28-30, 102, 103 and in LV myocardium of patients with terminal HF, increased diastolic 
tension consumes as much ATP and O2 as systolic tension, and elevated diastolic tension is 
a substantial energetic burden in failing hearts especially at higher heart rates.104 
 
In conclusion, whether OM has a neutral or even net energy-sparing effect on myocardial 
bioenergetics, or whether the drug´s net effect on myosin could increase O2-consumption is 
a question future research should continue to address. Furthermore, the development of 
small molecules targeting sarcomeric motor proteins is an emerging field that is discussed 
in more detail in the Online Supplement.  
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Alternative treatments targeting EC coupling  
 
Nitroxyl 
Nitroxyl (HNO) is produced by NO synthase under conditions of oxidative or nitrosative 
stress. HNO donated by Angeli’s salt (AS) improves cardiac function in normal and failing 
dogs, independently of β-AR signaling, with no change in cGMP levels.105, 106 In cardiac 
myocytes, HNO increases fractional shortening (FS) and Ca2+ transients with no involvement 
of cAMP/PKA or cGMP/protein kinase G signaling.107 Instead, HNO modifies cysteine 
residues to enhance Ca2+ handling and increase myofilament Ca2+ sensitivity. In particular, 
HNO alters the inhibitory interaction between phospholamban and SERCA2a in a redox-
dependent manner, improving SR Ca2+ uptake and release in isolated myocytes/hearts 
(Figure 7).108, 109 In addition, HNO modifies the actin-tropomyosin and myosin heavy chain-
myosin light chain 1 interactions, increasing Ca2+ sensitivity and force generation in intact 
and skinned muscles (Figure 7).110 
 
Whereas beneficial effects of NO signaling to cGMP may be lost in conditions of cardiac 
oxidative stress (by the high reactivity of NO with ROS), this does not occur with HNO, 
whose efficacy is preserved in conditions with altered redox balance.111, 112 Novel HNO 
donors (e.g. CXL-1020) are long-lasting and more specific. CXL-1020 has HNO-dependent 
positive inotropic and lusitropic effects in isolated cardiac myocytes in vitro and in whole 
animal studies in vivo, in both normal and failing conditions. Human phase I-IIa clinical trials 
were recently completed (NCT01092325, NCT01096043). In patients with systolic HF, CXL-
1020 reduced both left and right heart filling pressures and SVR, while increasing SV. Heart 
rate was unchanged, and arterial pressure declined modestly.113 Currently, an improved 
second-generation HNO donor, CXL-1427, is tested in Phase I and II trials on healthy 
volunteers and patients with HF (NCT02157506, NCT02819271).   
 
Other compounds and interventions 
The mechanisms and, where appropriate, clinical results of Istaroxime, SERCA2a gene 
therapy and EF hand proteins are discussed in the Online Supplement.   
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Energetic considerations 
Taken together, inotropic agents have three principal modes of action:  
 
1) Activation of the adrenergic system,  
2) sensitization of myofilaments to Ca2+ and  
3) reconstitution of cytosolic Ca2+ handling independent of adrenergic activation.  
 
The modes of action of inotropic drugs have important energetic consequences. Most 
cellular ATP is consumed by SERCA, NKA and myosin ATPase.114 A central mechanism to 
match ATP supply to demand is “parallel activation” by Ca2+,31 where Ca2+ activates both 
ATP consumption and -regeneration (Figures 3 and 8): Increases in [Ca2+]c accelerate ATP 
consumption by EC coupling, hastening respiration via ADP which oxidizes NADH and 
FADH2 at the respiratory chain. On the other hand, Ca2+ enters mitochondria to activate 
Krebs cycle dehydrogenases, accelerating NADH and FADH2 regeneration (Figure 8).31 
Consequently, hormones or drugs that increase Ca2+ handling (e.g., catecholamines) in the 
short term induce this “parallel activation” of respiration, maintaining the redox state of 
NADH and FADH2 in normal hearts (Figure 8).31 In the failing heart, however, mitochondrial 
Ca2+ uptake is impaired, resulting in NADH oxidation during β-adrenergic stimulation.31, 33 
Since NADH is coupled to the NADPH pool, and NADPH required for ROS detoxification 
(Figures 3 and 8), a mismatch between cardiac work and mitochondrial Ca2+ uptake 
induces oxidative stress.31, 33 This may contribute to arrhythmias, systolic dysfunction and 
maladaptive remodeling through necrosis and other redox-sensitive signaling pathways.33 
Therefore, improving SR Ca2+ content and release, as has been observed with 
AAV1/SERCA2a115 or HNO107 in animal models of HF, may improve the efficiency of 
mitochondrial Ca2+ uptake and make the failing heart less sensitive towards β-AR-mediated 
oxidative stress and damage. In patients with improved LVEF in response to β-blockers, 
SERCA gene expression was strongly upregulated,116 suggesting that also β-blockers may 
improve mitochondrial redox regulation through restoring defective EC coupling in the long 
term.  
 
Conversely, when sensitizing myofilaments to Ca2+, the increase in ATP consumption at the 
myofilaments may not be adequately matched by Ca2+-induced Krebs cycle activation in 
mitochondria (Figure 8). In fact, pre-stretching cardiac trabeculae increases force 
production independent of an increase in Ca2+ via the Frank Starling mechanism, which is 
related to myofilament Ca2+ sensitization, and this oxidizes NADH.117 Whether such 
energetic mismatch and possibly further downstream consequences such as energetic 
deficit and oxidative stress are also the result of Ca2+ sensitization through inotropic drugs 
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(i.e., EMD-57033, levosimendan, OM, nitroxyl etc.), mutations occurring in patients with 
HCM73, 74 and/or post-translational modifications occurring in patients with systolic HF103 
needs to be clarified by future research. In the context of inotropic drugs, however, a profile 
where Ca2+ sensitization is coupled to restoration of Ca2+ handling (i.e. nitroxyl) or increases 
of Ca2+ (i.e., levosimendan; table 3) may ameliorate energetic/redox mismatch occurring 
through Ca2+ sensitization per se.  
 
Finally, it should be considered whether targeting mitochondria may be an alternative 
indirect inotropic intervention, since in dogs with HF, elamipretide – which accumulates in 
mitochondria and improves mitochondrial function – acutely increased cardiac output by a 
similar extent (+25%)118 as OM (+22 and +29%, respectively; Table 3).93, 94 Furthermore, 
trimetazidine and perhexilline target substrate metabolism of mitochondria and improve 
LVEF, hemodynamics, cardiac energetics and symptoms in patients with HF (for more 
details on these compounds see Online Supplement).119-123 Finally, cardiac myocyte-
specific iron deficiency impaired the response to dobutamine in preclinical models of HF 
which could be restored by iron supplementation,124 suggesting that pharmacological 
restoration of mitochondrial function may also regenerate the heart´s response to inotropic 
stimulation.  
 
 
Summary 
Catecholamines and PDE-inhibitors are associated with excess mortality presumably 
related to the induction of arrhythmias in the short term and the activation of signaling 
pathways that aggravate maladaptive remodelling of the failing heart in the long term. 
Although levosimendan has so far been viewed as a Ca2+ sensitizer, its inotropic effect 
relies on PDE3-inhibition as well. As a myosin activator, OM improves systolic function 
without activating adrenergic signaling or increasing cytosolic Ca2+, but its therapeutic range 
is limited by diastolic dysfunction at higher doses. Nitroxyl restores cytosolic Ca2+ handling 
in failing hearts without activating cAMP-dependent signaling pathways and shows a 
promising hemodynamic profile, but its clinical usefulness awaits further clinical testing. 
Besides the impact of adrenergic signaling, bioenergetics aspects need to be considered to 
estimate the comprehensive profile and long-term consequences of any agent that affects 
inotropy.  
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Statements and recommendations 
Based on these preclinical and clinical data as well as the bioenergetic considerations, the 
Committees on Translational Research and on Acute Heart Failure of the HFA of the ESC 
make the following statements and recommendations:  
• Currently available drugs primarily targeting inotropy are cardiotropic glycosides, 
catecholamines (in particular, dobutamine), PDE-inhibitors and levosimendan.  
• According to the current HF Guidelines,3 the use of catecholamines, PDE-inhibitors 
and levosimendan should be limited to patients with hypotension (SBP <90 
mmHg) and/or signs/symptoms of hypoperfusion despite adequate filling status to 
increase cardiac output and improve peripheral perfusion to maintain end-organ 
function (IIb, C).  
• PDE-inhibitors and levosimendan can cause hypotension due to vasodilatory 
actions.   
• Vasopressors (preferably norepinephrine) may be considered to increase blood 
pressure and vital organ perfusion in patients with cardiogenic shock despite the 
use of inotropes (IIb, B).3  
• So far, all inotropic drugs recommended for the use in patients with acute HF 
(including levosimendan) activate adrenergic signaling at least to some extent.  
• Longer-term use of drugs that exclusively target adrenergic signaling 
(catecholamines, PDE-inhibitors) are associated with adverse outcome.   
• Levosimendan, with its hybrid Ca2+ sensitization and adrenergic action (PDE3 
inhibition), could be useful in selected patient populations, which may include 
patients treated with β-blockers.   
• Since mitochondrial function is intimately linked to cellular Ca2+ handling,31 the 
bioenergetic consequences of treatments targeting inotropy need to be considered 
to understand their short- and long-term consequences.  
• On theoretical grounds, treatments that restore the defects of cytosolic Ca2+ 
handling in the failing heart without activating adrenergic signaling may be a 
promising avenue since they avoid diastolic dysfunction and potentially bioenergetic 
mismatch of pure Ca2+ sensitization, but also adverse long-term consequences of 
adrenergic activation.  
• Future research should be directed towards deepening our understanding of the 
close interplay between EC coupling and mitochondrial energetics, since only 
the integration of these aspects will resolve the net biological effects of drugs 
targeting inotropy in the short- and long-term.  
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Figure legends 
 
 
Figure 1: The physiology of excitation-contraction coupling and how this is altered in 
systolic heart failure.   
AR, adrenergic receptor; PDE, phosphodiesterase; cAMP, cyclic adenosine 
monophosphate; PKA, protein kinase A; SR, sarcoplasmic reticulum; SERCA, SR Ca2+ 
ATPase; RyR, ryanodine receptor; ICa and INa, Ca2+ and Na+ currents; NCX; Na+/Ca2+-
exchanger; NKA, Na+/K+-ATPase; ETC, electron transport chain; T-tubule, transversal 
tubule. Red arrows (↑↓) indicate the direction of change in heart failure.  
 
 
Figure 2: Signal transduction of β1-adrenergic stimulation in cardiac myocytes and 
its impact on inotropy, but also arrhythmias, hypertrophy and apoptosis.  
ADR, adrenaline; NA, noradrenaline; AR, adrenergic receptor; AC, adenylyl cyclase; cAMP, 
cyclic adenosine monophosphate; PDE, phosphodiesterase; PKA, protein kinase A; EPAC, 
exchange protein directly activated by cAMP; 5’-AMP, 5’ adenosine monophosphate; 
CaMKII, Ca2+/calmodulin-dependent protein kinase II; GRK2, G-protein coupled receptor 
kinase 2; α, β, γ,  α-, β- and γ-subunits of the stimulatory G-protein.    
 
 
Figure 3: Interplay between EC coupling and mitochondrial energetics.  
Krebs cycle activity is controlled by Ca2+, and mitochondrial Ca2+ uptake is diminished in 
heart failure by changes in cytosolic Ca2+ and Na+ handling. This provokes an energetic 
deficit and oxidative stress, which further impairs EC coupling and aggravates systolic and 
diastolic function.  
Nnt, nicotinamide nucleotide transhydrogenase; ETC, electron transport chain; ATPase, 
F1Fo-ATP synthase; IDPm, isocitrate dehydrogenase; Mn-SOD, mitochondrial superoxide 
dismutase; CK, creatine kinase; Cr, creatine; PCr, phosphocreatine; SERCA, SR Ca2+ 
ATPase; RyR, ryanodine receptor; late INa, late Na+ current; NCLX, mitochondrial Na+/Ca2+-
exchanger; MCU, mitochondrial Ca2+ uniporter; CaMKII, Ca2+/calmodulin-dependent protein 
kinase II; AR, adrenergic receptor. Red arrows (↑↓) indicate the direction of change in heart 
failure. 
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Figure 4: Mechanisms of action of cardiotonic glycosides (CTG) and istaroxime 
(ISTA).  
ROS, reactive oxygen species; SR, sarcoplasmic reticulum; SERCA, SR Ca2+ ATPase; 
RyR, ryanodine receptor; ICa and INa, Ca2+ and Na+ currents; NCX; Na+/Ca2+-exchanger; 
NKA, Na+/K+-ATPase; NCLX, mitochondrial Na+/Ca2+-exchanger; TCA, tricarboxylic acid 
(Krebs) cycle. Red arrows (↑↓) indicate the direction of change in response to CTG.   
 
 
Figure 5: Mode of action of levosimendan and its active metabolite OR-1896.  
Both Ca2+-sensitization and PDE3-inhibition at nanomolar concentrations ([nM]) contribute 
to their inotropic and lusitropic effects. Activation of mitochondrial KATP (mitoKATP) channels 
at micromolar concentrations ([µM]) may provide protection against ischemia/reperfusion.     
AR, adrenergic receptor; PDE, phosphodiesterase; cAMP, cyclic adenosine 
monophosphate; PKA, protein kinase A; SR, sarcomplasmic reticulum; SERCA, SR Ca2+ 
ATPase; RyR, ryanodine receptor; ICa and INa, Ca2+ and Na+ currents; NCX; Na+/Ca2+-
exchanger; NKA, Na+/K+-ATPase; ETC, electron transport chain; T-tubule, transversal 
tubule. Red arrows (↑↓) indicate the direction of change in heart failure, while green arrows 
(↑↓) indicate the direction induced by levosimendan.  
 
 
Figure 6: Mechanism of action and effects of omecamtiv mecarbil.  
A, The mechanochemical cycle of myosin. Yellow indicates myosin weakly bound to actin, 
while red indicates the myosin strongly bound to actin. Omecamtiv mecarbil (OM) 
accelerates the transition rate of myosin into the strongly actin-bound force-generating 
state. B, Representative tracings showing that OM (200 nM) increases the time and 
amplitude of myocyte shortening without any effect on the cytosolic Ca2+ transient. In 
contrast, the β-AR agonist isoproterenol increases myocyte shortening through increasing 
cytosolic Ca2+ transients. Fractional systolic sarcomere shortening and diastolic cell length 
(C) as well as time to peak and maximal relaxation velocity (D) in isolated rat cardiac 
myocytes in response to escalating concentrations of OM. A-D are from Malik et al. 93 with 
permission. E, Impact of OM (20 min infusion at a dose that prolonged SET by 20%) on LV 
pressure-volume loops in a pig model of myocardial stunning (termed “post-ischemic” 
heart). The volumes indicate LV stroke volume and end-diastolic volume, of which EF is 
calculated. Taken from Bakkehaug et al. 96 with permission. F, The impact of OM at 0.1 or 1 
µM on normalized isometric force in response to increasing Ca2+ concentrations 
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(decreasing pCa) in skinned rat cardiac myocytes. Taken from Nagy et al. 99 with 
permission. 
 
 
Figure 7: Mechanisms of action of nitroxyl (HNO) in HF. HNO affects redox-
sensitive residues of various proteins involved in myocyte Ca2+ handling. In 
particular, HNO increases SERCA activity and sensitizes myofilaments to Ca2+. In 
concert, these properties increase SR Ca2+ load, systolic Ca2+ transients and 
contraction. Red arrows (↑↓) indicate the direction of change in heart failure, while 
green arrows (↑↓) indicate the direction induced by HNO.  
 
 
Figure 8: Known and hypothesized bioenergetic consequences of inotropic 
interventions that either increase cytosolic Ca2+ or myofilament Ca2+ sensitivity. ECC, 
excitation-contraction coupling; ETC, electron transport chain; MCU, mitochondrial Ca2+ 
uptake.  
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